       Document 0069
 DOCN  M9620069
 TI    The impact of initiating a human immunodeficiency virus screening
       program in an urban obstetric population.
 DT    9602
 AU    Lewis R; O'Brien JM; Ray DT; Sibai BM; Department of Obstetrics and
       Gynecology, University of Tennessee,; Memphis 38103, USA.
 SO    Am J Obstet Gynecol. 1995 Oct;173(4):1329-33. Unique Identifier :
       AIDSLINE MED/96041809
 AB    OBJECTIVE: Our purpose was to describe the incidence of human
       immunodeficiency virus infection and to assess the cost/benefit ratio of
       universal antenatal human immunodeficiency virus screening. STUDY
       DESIGN: Medical records of women in this urban obstetrics population,
       from the years 1988 to 1993, were examined. The incidence of known human
       immunodeficiency virus seropositivity at delivery was determined. The
       costs of performing human immunodeficiency virus screening, evaluating
       the disease status, and administering therapy were calculated. These
       costs were compared with an averaged cost for care and follow-up of
       infants infected through vertical transmission. RESULTS: The incidence
       of known human immunodeficiency virus seropositivity at delivery
       approximately doubled since the initiation of a human immunodeficiency
       virus screening program (0.26% to 0.48%). Obstetric screening added an
       approximate $100,000 to medical costs. The calculated cost of pediatric
       follow-up of human immunodeficiency virus-seropositive infants for the
       first 18 months was estimated at $344,355. In our population, with
       universal screening and zidovudine therapy, the medical costs could be
       reduced by $175,500 per year. CONCLUSION: A program of voluntary human
       immunodeficiency virus screening increases the incidence of known human
       immunodeficiency virus infection. Offering screening and follow-up to
       all pregnant patients in an urban setting is both cost-effective and
       medically beneficial.
 DE    Adult  Comparative Study  Cost-Benefit Analysis  Female  Health Care
       Costs  Human  HIV Infections/ECONOMICS/EPIDEMIOLOGY/*PREVENTION &
       CONTROL  HIV Seropositivity/ECONOMICS/EPIDEMIOLOGY  Incidence  Infant
       Infant, Newborn  *Mass Screening/ECONOMICS  Pregnancy  Pregnancy
       Complications, Infectious/ECONOMICS/EPIDEMIOLOGY/  *PREVENTION & CONTROL
       *Prenatal Care  *Urban Health  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

